3o9b: Difference between revisions

From Proteopedia
Jump to navigation Jump to search
← Older edit
No edit summary
No edit summary
 
Line 3: Line 3:
<StructureSection load='3o9b' size='340' side='right'caption='[[3o9b]], [[Resolution|resolution]] 1.50&Aring;' scene=''>
<StructureSection load='3o9b' size='340' side='right'caption='[[3o9b]], [[Resolution|resolution]] 1.50&Aring;' scene=''>
== Structural highlights ==
== Structural highlights ==
<table><tr><td colspan='2'>[[3o9b]] is a 2 chain structure with sequence from [https://en.wikipedia.org/wiki/9hiv1 9hiv1]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=3O9B OCA]. For a <b>guided tour on the structure components</b> use [https://proteopedia.org/fgij/fg.htm?mol=3O9B FirstGlance]. <br>
<table><tr><td colspan='2'>[[3o9b]] is a 2 chain structure with sequence from [https://en.wikipedia.org/wiki/Human_immunodeficiency_virus_1 Human immunodeficiency virus 1]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=3O9B OCA]. For a <b>guided tour on the structure components</b> use [https://proteopedia.org/fgij/fg.htm?mol=3O9B FirstGlance]. <br>
</td></tr><tr id='ligand'><td class="sblockLbl"><b>[[Ligand|Ligands:]]</b></td><td class="sblockDat" id="ligandDat"><scene name='pdbligand=ACT:ACETATE+ION'>ACT</scene>, <scene name='pdbligand=GOL:GLYCEROL'>GOL</scene>, <scene name='pdbligand=K2A:(3R,3AS,6AR)-HEXAHYDROFURO[2,3-B]FURAN-3-YL+[(1S,2R)-1-BENZYL-2-HYDROXY-3-({[4-(HYDROXYMETHYL)PHENYL]SULFONYL}[(2S)-2-METHYLBUTYL]AMINO)PROPYL]CARBAMATE'>K2A</scene>, <scene name='pdbligand=PO4:PHOSPHATE+ION'>PO4</scene></td></tr>
</td></tr><tr id='method'><td class="sblockLbl"><b>[[Empirical_models|Method:]]</b></td><td class="sblockDat" id="methodDat">X-ray diffraction, [[Resolution|Resolution]] 1.5&#8491;</td></tr>
<tr id='related'><td class="sblockLbl"><b>[[Related_structure|Related:]]</b></td><td class="sblockDat"><div style='overflow: auto; max-height: 3em;'>[[3o99|3o99]], [[3o9a|3o9a]], [[3o9c|3o9c]], [[3o9d|3o9d]], [[3o9e|3o9e]], [[3o9f|3o9f]], [[3o9g|3o9g]], [[3o9h|3o9h]], [[3o9i|3o9i]]</div></td></tr>
<tr id='ligand'><td class="sblockLbl"><b>[[Ligand|Ligands:]]</b></td><td class="sblockDat" id="ligandDat"><scene name='pdbligand=ACT:ACETATE+ION'>ACT</scene>, <scene name='pdbligand=GOL:GLYCEROL'>GOL</scene>, <scene name='pdbligand=K2A:(3R,3AS,6AR)-HEXAHYDROFURO[2,3-B]FURAN-3-YL+[(1S,2R)-1-BENZYL-2-HYDROXY-3-({[4-(HYDROXYMETHYL)PHENYL]SULFONYL}[(2S)-2-METHYLBUTYL]AMINO)PROPYL]CARBAMATE'>K2A</scene>, <scene name='pdbligand=PO4:PHOSPHATE+ION'>PO4</scene></td></tr>
<tr id='gene'><td class="sblockLbl"><b>[[Gene|Gene:]]</b></td><td class="sblockDat">gag-pol, pol ([https://www.ncbi.nlm.nih.gov/Taxonomy/Browser/wwwtax.cgi?mode=Info&srchmode=5&id=11676 9HIV1])</td></tr>
<tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[https://proteopedia.org/fgij/fg.htm?mol=3o9b FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=3o9b OCA], [https://pdbe.org/3o9b PDBe], [https://www.rcsb.org/pdb/explore.do?structureId=3o9b RCSB], [https://www.ebi.ac.uk/pdbsum/3o9b PDBsum], [https://prosat.h-its.org/prosat/prosatexe?pdbcode=3o9b ProSAT]</span></td></tr>
<tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[https://proteopedia.org/fgij/fg.htm?mol=3o9b FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=3o9b OCA], [https://pdbe.org/3o9b PDBe], [https://www.rcsb.org/pdb/explore.do?structureId=3o9b RCSB], [https://www.ebi.ac.uk/pdbsum/3o9b PDBsum], [https://prosat.h-its.org/prosat/prosatexe?pdbcode=3o9b ProSAT]</span></td></tr>
</table>
</table>
<div style="background-color:#fffaf0;">
== Function ==
== Publication Abstract from PubMed ==
[https://www.uniprot.org/uniprot/Q90K99_9HIV1 Q90K99_9HIV1]
The rapid evolution of HIV under selective drug pressure has led to multidrug resistant (MDR) strains that evade standard therapies. We designed highly potent HIV-1 protease inhibitors (PIs) using the substrate envelope model, which confines inhibitors within the consensus volume of natural substrates, providing inhibitors less susceptible to resistance because a mutation affecting such inhibitors will simultaneously affect viral substrate processing. The designed PIs share a common chemical scaffold but utilize various moieties that optimally fill the substrate envelope, as confirmed by crystal structures. The designed PIs retain robust binding to MDR protease variants and display exceptional antiviral potencies against different clades of HIV as well as a panel of 12 drug-resistant viral strains. The substrate envelope model proves to be a powerful strategy to develop potent and robust inhibitors that avoid drug resistance.
 
Substrate envelope-designed potent HIV-1 protease inhibitors to avoid drug resistance.,Nalam MN, Ali A, Reddy GS, Cao H, Anjum SG, Altman MD, Yilmaz NK, Tidor B, Rana TM, Schiffer CA Chem Biol. 2013 Sep 19;20(9):1116-24. doi: 10.1016/j.chembiol.2013.07.014. Epub, 2013 Sep 5. PMID:24012370<ref>PMID:24012370</ref>
 
From MEDLINE&reg;/PubMed&reg;, a database of the U.S. National Library of Medicine.<br>
</div>
<div class="pdbe-citations 3o9b" style="background-color:#fffaf0;"></div>
== References ==
<references/>
__TOC__
__TOC__
</StructureSection>
</StructureSection>
[[Category: Human immunodeficiency virus 1]]
[[Category: Large Structures]]
[[Category: Large Structures]]
[[Category: Nalam, M N.L]]
[[Category: Nalam MNL]]
[[Category: Schiffer, C A]]
[[Category: Schiffer CA]]
[[Category: Aid]]
[[Category: Aspartyl protease]]
[[Category: Drug design]]
[[Category: Drug resistance]]
[[Category: Hiv-1 protease]]
[[Category: Hydrolase-hydrolase inhibitor complex]]
[[Category: Protease inhibitor]]

Latest revision as of 13:04, 14 February 2024

Crystal Structure of wild-type HIV-1 Protease in Complex with kd25Crystal Structure of wild-type HIV-1 Protease in Complex with kd25

Structural highlights

3o9b is a 2 chain structure with sequence from Human immunodeficiency virus 1. Full crystallographic information is available from OCA. For a guided tour on the structure components use FirstGlance.
Method:X-ray diffraction, Resolution 1.5Å
Ligands:, , ,
Resources:FirstGlance, OCA, PDBe, RCSB, PDBsum, ProSAT

Function

Q90K99_9HIV1

3o9b, resolution 1.50Å

Drag the structure with the mouse to rotate

Proteopedia Page Contributors and Editors (what is this?)Proteopedia Page Contributors and Editors (what is this?)

OCA
Retrieved from "https://proteopedia.openfox.io/wiki/index.php?title=3o9b&oldid=4059928"